Brazil at a glance
- Population
- 212.8 million 2025
- Life expectancy at birth
- 76.0 years, 2024
- People aged 65 and over
- 11.5 % of people, 2025
- Health spending per person
- 1,010 US$ per person, 2023
- Doctors
- 2.36 per 1,000 people, 2023
Updated
Reviewed by Vidhi Upadhyay
Brazil Antimicrobial Resistance Diagnostics Market Industry Trends and Forecast to 2034: Segmented by (Technology, Setting, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034
Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.
Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.
$106.5 Mn total, 2026–2034
| Year | Market size | Change that year | Since 2025 |
|---|---|---|---|
| 2024 (estimate) | $92.1 Mn | — | — |
| 2025 (base) | $99.9 Mn | +$7.7 Mn | — |
| 2026 (forecast) | $108.3 Mn | +$8.4 Mn | +8.4% |
| 2027 (forecast) | $117.4 Mn | +$9.1 Mn | +17.5% |
| 2028 (forecast) | $127.2 Mn | +$9.9 Mn | +27.4% |
| 2029 (forecast) | $137.9 Mn | +$10.7 Mn | +38.1% |
| 2030 (forecast) | $149.5 Mn | +$11.6 Mn | +49.7% |
| 2031 (forecast) | $162.1 Mn | +$12.6 Mn | +62.2% |
| 2032 (forecast) | $175.7 Mn | +$13.6 Mn | +75.9% |
| 2033 (forecast) | $190.4 Mn | +$14.8 Mn | +90.6% |
| 2034 (forecast) | $206.4 Mn | +$16.0 Mn | +106.7% |
Placeholder estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.
| Market size, 2025 | $99.9 Mn placeholder estimate |
|---|---|
| Forecast, 2034 | $206.4 Mn placeholder estimate |
| Growth (CAGR), 2025–2034 | 8.4% placeholder estimate |
| Years | 2024 historical · 2025 base year · 2026–2034 forecast |
| Segments | Technology, setting and end user (see all) |
| Key players | bioMérieux SA, BD (Becton, Dickinson), Beckman Coulter (Danaher), Accelerate Diagnostics, Inc., Thermo Fisher Scientific Inc. (see all) |
| Regulator in Brazil | ANVISASource: ANVISA. Checked 14 Nov 2026. |
| Formats | PDF, PPTX, XLSX |
Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.
Antimicrobial resistance diagnostics show which antibiotics will work against an infection, helping doctors avoid ineffective drugs.
Key segments of the antimicrobial Resistance Diagnostics market include technology (Automated AST Systems, Molecular Resistance Tests and Rapid Phenotypic AST) and setting (Hospital Labs and Reference Labs).
Rising antimicrobial resistance, outbreaks of new and returning diseases, climate change spreading infections and strong global funding for prevention are driving the antimicrobial Resistance Diagnostics market.
New vaccines, rapid tests and public-private funding for neglected diseases give the antimicrobial Resistance Diagnostics market room to grow, especially in Asia, Africa and Latin America.
Low prices in poorer markets, weak returns for new antibiotics, vaccine hesitancy and cold-chain problems hold back the antimicrobial Resistance Diagnostics market.
The antimicrobial Resistance Diagnostics market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.
Medical devices are notified to or registered with ANVISA, the National Health Surveillance Agency, depending on their risk class.[1] The Unified Health System (SUS) gives free public care to everyone, and CONITEC advises which medicines and technologies it adds.[2]
Medical device rules, such as the US FDA 510(k) and PMA pathways and the EU Medical Device Regulation, govern how antimicrobial Resistance Diagnostics products are approved and monitored. Reimbursement codes and hospital purchasing policies decide how widely they are used in Brazil.
What doctors and scientists are doing in Antimicrobial Resistance Diagnostics right now, from free public sources.
Sources: PubMed (US National Library of Medicine), ClinicalTrials.gov, World Bank. Fetched 12 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.
[1] World Bank Open Data, Health spending per person (US$ per person). Retrieved 17 Nov 2026.
[2] World Bank Open Data, Doctors (per 1,000 people). Retrieved 18 Nov 2026.
[3] World Bank Open Data, People aged 65 and over (% of people). Retrieved 18 Nov 2026.
From our blog
Brazil
Brazil
Brazil
Brazil
Brazil
Brazil
Digital Health · Brazil
Healthcare Services · Brazil
Pharmaceuticals · Brazil
OTC & Nutraceuticals · Brazil
Pharmaceuticals · Brazil
OTC & Nutraceuticals · Brazil